Obesity is a worldwide health problem at increasing incidence associated with high
morbidity and mortality. Although obesity increases patients' cardiovascular (CV) risk, more …

Obesity, a chronic disease established as a global epidemic by the World Health
Organization, is considered a risk factor for atrial fibrillation (AF), the most common …

Objectives Obesity is associated with increased risks of atrial fibrillation (AF) and venous
thromboembolism (VTE) for which anticoagulation is commonly used. However, data on the …

Oral anticoagulation is obligatory in patients with atrial fibrillation (AF) to prevent
thromboembolic stroke. Direct direct oral anticoagulants (DOAC) exhibit improved safety …

Although nonvitamin K antagonist oral anticoagulants (NOACs) have generally shown
comparable efficacy and better safety compared with warfarin, atrial fibrillation (AF) patients …

In the last 40 years, concern about the obesity epidemic has increased. Data from the
current literature highlight a strong relationship between obesity and atrial fibrillation (AF) …

The prevalence of both atrial fibrillation (AF) and obesity has steadily increased. Nonvitamin
K antagonist oral anticoagulants (NOACs) have been shown to be more effective and safer …

Introduction: Obese and morbidly obese patients are under-represented in clinical trials of
non-vitamin K oral anticoagulants (NOAC). Patients with atrial fibrillation (AF) and …

Background and aim Atrial fibrillation (AF) is the most frequently observed cardiac
arrhythmia in clinical settings. Obesity can influence the efficacy of the treatment …

Introduction Current guidelines and consensus statements have advised against the use of
direct oral anticoagulants (DOACs) for morbidly obese patients (BMI> 40 kg/m2), indicating …